Response of fibroblastic rheumatism to infliximab.
Onset is usually sudden with symmetrical articular involvement of both small and large joints, occurrence of solid skin nodules, and rapid progression. Treatment is generally unrewarding. Here we report a severe and disabling case of FR responding favorably to infliximab therapy. After 32 weeks of continuous treatment, skin lesions dramatically improved and arthropathy partially regressed.
Romiti
Ricardo
R
Departments of Dermatology and Rheumatology, University of São Paulo, 05403-000 São Paulo, SP, Brazil.
Levy Neto
Mauricio
M
Menta Simonsen Nico
Marcello
M